Bristol-Myers Squibb Company

Bristol-Myers Squibb (BMY) is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for serious diseases. Its portfolio spans oncology, immunology, cardiovascular, and fibrosis areas. Key products include Opdivo (nivolumab) for cancer, Eliquis (apixaban) for blood clots, and Orencia (abatacept) for autoimmune conditions. The company operates through a single segment, with revenue primarily from branded prescription drugs.

Revenue is generated through sales of proprietary drugs, with Opdivo and Eliquis being top contributors. In the latest fiscal year, total revenue was approximately $48.5 billion. The company invests heavily in R&D to sustain its pipeline. It also earns royalties and licensing fees from partnerships. Gross margin is high at 71%, reflecting the premium pricing of innovative drugs.

BMY competes in the highly competitive drug manufacturing industry, alongside Pfizer, Merck, and AbbVie. It differentiates through a strong oncology franchise and a robust pipeline. The company holds a leading position in immuno-oncology with Opdivo. Despite patent expirations on some drugs, BMY maintains a solid market position through acquisitions and new drug launches.

BMY's customers include healthcare providers, hospitals, and patients. Its primary geographic markets are the United States (over 60% of revenue) and international markets, including Europe and Japan. The company targets patients with serious diseases, particularly cancer and cardiovascular conditions, and works with insurers and government health programs for reimbursement.

An auto-generated descriptive profile based on company data, for informational purposes only.